American Century Companies Inc. Decreases Holdings in DaVita Inc. (NYSE:DVA)

American Century Companies Inc. lowered its stake in DaVita Inc. (NYSE:DVA) by 20.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,772 shares of the company’s stock after selling 17,775 shares during the period. American Century Companies Inc. owned approximately 0.08% of DaVita worth $9,668,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of DVA. 8 Knots Management LLC bought a new position in DaVita during the 4th quarter valued at about $89,504,000. Doma Perpetual Capital Management LLC purchased a new stake in shares of DaVita in the fourth quarter worth approximately $53,076,000. Norges Bank purchased a new position in DaVita during the 4th quarter valued at $36,626,000. Allianz Asset Management GmbH grew its position in DaVita by 63.9% in the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after acquiring an additional 213,992 shares during the last quarter. Finally, Pinebridge Investments L.P. lifted its position in shares of DaVita by 148.8% during the fourth quarter. Pinebridge Investments L.P. now owns 268,601 shares of the company’s stock worth $28,139,000 after purchasing an additional 160,630 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Insider Activity

In other DaVita news, CEO Javier Rodriguez sold 32,176 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Javier Rodriguez sold 32,176 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at $141,219,407.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total value of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The disclosure for this sale can be found here. Over the last three months, insiders have sold 173,482 shares of company stock valued at $27,387,069. Company insiders own 2.00% of the company’s stock.

DaVita Price Performance

NYSE DVA opened at $164.00 on Monday. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94. The firm has a market capitalization of $14.38 billion, a P/E ratio of 18.64, a P/E/G ratio of 0.95 and a beta of 0.87. DaVita Inc. has a 12-month low of $71.51 and a 12-month high of $166.04. The firm’s fifty day simple moving average is $147.64 and its two-hundred day simple moving average is $141.23.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The company had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. DaVita’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period last year, the business earned $2.08 EPS. Analysts forecast that DaVita Inc. will post 9.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. StockNews.com downgraded shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 8th. Truist Financial increased their price target on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Tuesday, August 20th. Bank of America increased their price objective on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. Finally, TD Cowen boosted their price target on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, DaVita has a consensus rating of “Hold” and a consensus target price of $157.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.